MedPath

Incorporating teleCBIT Into a Hospital-Based Tic Program

Not Applicable
Completed
Conditions
Tourette Syndrome
Tic Disorders
Interventions
Behavioral: teleCBIT
Registration Number
NCT04007913
Lead Sponsor
San Jose State University
Brief Summary

This is a single-arm open trial of Comprehensive Behavioral Intervention for Tics (CBIT) delivered to pediatric and adult patients with persistent tic disorders in their homes via videoconferencing (i.e., teleCBIT). All participants who enroll will receive teleCBIT.

Detailed Description

Comprehensive Behavioral Intervention for Tics (CBIT) is a behavioral therapy with proven efficacy for treating persistent tic disorders (e.g., Tourette Syndrome) in youth and adults. Lack of access to a local CBIT provider prevents treatment access for many patients who could benefit from CBIT. Providing CBIT to patients in their homes via videoconferencing technology (i.e., teleCBIT) is a promising approach to increasing CBIT access. This study investigates treatment uptake, acceptability, feasibility, and clinical effectiveness of teleCBIT among pediatric and adult patients enrolled as patients in a state-of-the-art medical tic program.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
31
Inclusion Criteria
  • age 5-65, diagnosis of Tourette Syndrome or other persistent tic disorder (per diagnostic interview and self-report of prior physician diagnosis)
  • Clinical Global Impressions - Severity Score > 3 (i.e., "moderately ill" or worse),
  • unmedicated or on stable medication treatment for tics and psychiatric problems,
  • fluency in English
  • a functional accessible home computer and high speed (i.e., cable/DSL) internet connection
  • willingness to sign a release of information to contact a local, licensed medical or mental health provider, of whom they are currently a patient (in case of emergent safety concerns).
  • Minor participants must have a parent or guardian who is fluent in English available to attend treatment and assessment sessions.
Exclusion Criteria
  • significant suicidality, (i.e., a score of > 12 on the MINI or MINI-Kid suicidality module);
  • prior diagnoses of intellectual disability; pervasive developmental disorder, mania, schizophrenia, psychotic disorder, substance abuse, substance dependence, or conduct disorder; currently experiencing a psychosocial, psychiatric, or neurological problem that requires immediate care
  • lack of a functional home computer with high speed (i.e., cable or DSL) internet connection;
  • or, prior receipt of >3 previous sessions of behavior therapy for tics within the past year (per self/parent report)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
teleCBITteleCBITPatient receive eight sessions of individual teleCBIT, in accordance with Woods et al's (2008) protocol, from a licensed psychologist.
Primary Outcome Measures
NameTimeMethod
Change in Yale Global Tic Severity Scale Tic Severity Score (YGTSS)Change from pre-treatment (i.e., week 0) to post-treatment (i.e., 10-week)

YGTSS Tic Severity Score (0-50) as rated by independent evaluator. Higher scores indicate more severe tics.

Secondary Outcome Measures
NameTimeMethod
Clinical Global Impression: Improvement (CGI:I) ScoreCGI:I score at post-treatment (Week 10), which assesses change from pre-treatment (i.e., week 0)

CGI:I scores (range: 1-7) describe the global level of change in clinical severity of a disorder. Lower scores indicate more favorable change over time. Following common practice, we will also dichotomize CGI:I scores to evaluate Clinical Responder Status according to CGI:I score (i.e., responder: CGI:I=1 or 2; non-responder=CGI:I\>2)

Adult Tic Questionnaire (ATQ) Total Tic Severity ScoreChange from pre-treatment (i.e., week 0) to post-treatment (i.e., 10-week)

Adult Tic Severity as measured by self-report on the ATQ (range: 0-224). Higher scores indicate more severe tics.

Yale Global Tic Severity Scale (YGTSS) Impairment ScoreChange from pre-treatment (i.e., week 0) to post-treatment (i.e., 10-week)

YGTSS Impairment Score (0-50) as rated by independent evaluator. Higher scores indicate greater tic-related impairment

Parent Tic Questionnaire (PTQ) Total Tic Severity ScoreChange from pre-treatment (i.e., week 0) to post-treatment (i.e., 10-week)

Child Tic Severity as measured by parent-report on the PTQ (range: 0-224). Higher scores indicate more severe tics.

Trial Locations

Locations (2)

San Jose State University

🇺🇸

San Jose, California, United States

University of Florida Health

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath